Compare Neogen Chemicals with Similar Stocks
Dashboard
Low ability to service debt as the company has a high Debt to EBITDA ratio of 8.54 times
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 8.54 times
- The company has been able to generate a Return on Equity (avg) of 9.65% signifying low profitability per unit of shareholders funds
Poor long term growth as Operating profit has grown by an annual rate 13.43% of over the last 5 years
With a fall in PBT of -39.95%, the company declared Very Negative results in Dec 25
With ROCE of 5.9, it has a Very Expensive valuation with a 2.5 Enterprise value to Capital Employed
Stock DNA
Specialty Chemicals
INR 3,458 Cr (Small Cap)
119.00
39
0.08%
1.23
4.41%
4.32
Total Returns (Price + Dividend) 
Latest dividend: 1 per share ex-dividend date: Sep-19-2025
Risk Adjusted Returns v/s 
Returns Beta
News

Neogen Chemicals Ltd Valuation Surges to Very Expensive Amid Mixed Returns
Neogen Chemicals Ltd has witnessed a marked shift in its valuation parameters, moving from an already expensive rating to a very expensive classification. This change, coupled with a strong recent price rally, raises questions about the stock’s price attractiveness relative to its historical averages and peer group within the specialty chemicals sector.
Read full news article
Neogen Chemicals Ltd is Rated Strong Sell
Neogen Chemicals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 16 March 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 08 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read full news article
Neogen Chemicals Ltd Surges 7.12% to Day's High of Rs 1290.25 — Outperforms Sector by 2.88 Percentage Points
The Sensex advanced 3.59% on 8 Apr 2026, yet Neogen Chemicals Ltd outpaced both the benchmark and its sector peers with a 7.12% gain, reaching an intraday high of Rs 1290.25. This 2.88-percentage-point outperformance signals a stock-specific momentum shift rather than a mere market tailwind.
Read full news article Announcements 
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.
01-Apr-2026 | Source : BSEThe Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on March 30 2026 for Dr. Harin Haridas Kanani
Shareholder Meeting / Postal Ballot-Scrutinizers Report
30-Mar-2026 | Source : BSEVoting results and Scrutinizers report i.r.o. evoting on the agenda as mentioned in notice of EGM held on 29-03-2026
Shareholder Meeting / Postal Ballot-Outcome of EGM
29-Mar-2026 | Source : BSEProceedings of EGM held on 29-03-2026 at 11.30 a.m and concluded at 11.56 a.m.
Corporate Actions 
No Upcoming Board Meetings
Neogen Chemicals Ltd has declared 10% dividend, ex-date: 19 Sep 25
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Promoters
None
Held by 13 Schemes (19.82%)
Held by 38 FIIs (4.57%)
Haridas Kanani Family Trust (beena Haridas Kanani And Harin Haridas Kanani) (20.0%)
Sbi Contra Fund (8.85%)
15.3%
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
QoQ Growth in quarter ended Dec 2025 is 5.44% vs 11.74% in Sep 2025
QoQ Growth in quarter ended Dec 2025 is 9.50% vs -67.15% in Sep 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 5.91% vs 14.31% in Sep 2024
Growth in half year ended Sep 2025 is -39.18% vs 26.83% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 7.08% vs 17.05% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -46.58% vs 73.09% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is 12.58% vs 0.65% in Mar 2024
YoY Growth in year ended Mar 2025 is -2.30% vs -28.66% in Mar 2024






